5447-47-2

Usage

Uses

Used in Pharmaceutical Industry:
2,3-DIHYDRO-1H-CYCLOPENTA[B]QUINOLINE-9-CARBOXYLIC ACID is used as a building block for the synthesis of various pharmaceutical drugs due to its unique chemical structure and potential pharmacological properties.
Used in Anti-inflammatory Applications:
2,3-DIHYDRO-1H-CYCLOPENTA[B]QUINOLINE-9-CARBOXYLIC ACID is used as an anti-inflammatory agent for its potential to modulate inflammatory pathways and alleviate inflammation-related symptoms.
Used in Antimicrobial Applications:
2,3-DIHYDRO-1H-CYCLOPENTA[B]QUINOLINE-9-CARBOXYLIC ACID is used as an antimicrobial agent for its potential to inhibit the growth of harmful microorganisms and combat infections.
Used in Drug Development for Medical Conditions:
2,3-DIHYDRO-1H-CYCLOPENTA[B]QUINOLINE-9-CARBOXYLIC ACID is used in the research and development of new drug treatments for various medical conditions, leveraging its pharmacological properties and potential therapeutic applications.

InChI:InChI=1/C13H11NO2/c15-13(16)12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-2,4,6H,3,5,7H2,(H,15,16)

Upstream product

• 91-56-5 indole-2,3-dione 
• 120-92-3 cyclopentanone 

Relevant academic research and scientific papers

Structural Optimization of 2,3-Dihydro-1H-cyclopenta[ b]quinolines Targeting the Noncatalytic RVxF Site of Protein Phosphatase 1 for HIV-1 Inhibition

Combination antiretroviral therapy (cART) suppresses human immunodeficiency virus-1 (HIV-1) replication but is unable to permanently eradicate HIV-1. Importantly, cART does not target HIV-1 transcription, which is reactivated in latently infected reservoirs, leading to HIV-1 pathogenesis including non-infectious lung, cardiovascular, kidney, and neurodegenerative diseases. To address the limitations of cART and to prevent HIV-1-related pathogenesis, we developed small molecules to target the noncatalytic RVxF-accommodating site of protein phosphatase-1 (PP1) to prevent HIV-1 transcription activation. The PP1 RVxF-accommodating site is critical for the recruitment of regulatory and substrate proteins to PP1. Here, we confirm that our previously developed 1E7-03 compound binds to the PP1 RVxF-accommodating site. Iterative chemical alterations to 1E7-03 furnished a new analogue, HU-1a, with enhanced HIV-1 inhibitory activity and improved metabolic stability compared to 1E7-03. In a Split NanoBit competition assay, HU-1a primarily bound to the PP1 RVxF-accommodating site. In conclusion, our study identified HU-1a as a promising HIV-1 transcription inhibitor and showed that the PP1 RVxF-accommodating site is a potential drug target for the development of novel HIV-1 transcription inhibitors.

A simple one-pot synthesis of quinoline-4-carboxylic acid derivatives by Pfitzinger reaction of isatin with ketones in water

An improved Pfitzinger condensation reaction performed under acidic conditions is established. It provides a simple and efficient synthetic method for some useful quinoline-4-carboxylic acid derivatives using isatins and ketones that cannot be obtained ea